Varda Space Industries announced a $251 million Series D to advance pharmaceutical manufacturing in space, continuing a wave of investment into orbital platforms intended to support new ways of producing biologics. The funding underlines the business case for microgravity as a manufacturing environment and positions Varda as a key player in the effort to industrialize space-based production for medicines and related materials. Regulatory, scale-up, and quality-system requirements will remain central as the model shifts from lab proof to repeatable commercial manufacturing—an area where space-enabled supply chains could become a differentiator if technical hurdles are cleared.